Abstracts tagged "Lupus nephritis"

Abstract Number: L12 • ACR Convergence 2024
A-319, a CD3 X CD19 T Cell Engager (TCE), for the Treatment of Severe/Refractory SLE: Early Evidence of Rapid Reset of Disease-Specific Autoimmunity
Chunli Mei¹, Xin Guan¹, Bin Wu², Mengjiao Li¹, Xiaojing Liu¹, Xi Chen¹, You Song¹, Weiwei Wang¹, Cheng Wang¹, Huiling Mei¹, Xiaoru Duan¹, Lijuan Jiang¹, Wenlin Qiu¹, Likai Yu¹, Yuhong Liu¹, Xing Zhao³, Xuanfan Zhong³, Shengjie Xue³, Wuzhong Shen³, Ying Tan³, Guojian Yu³, Guiyun Tu³, Hanyang Chen³, Amy Sun³, Xiaoqiang Yan³, Anbing Huang¹, Rong Du¹ and Qiubai Li¹, ¹Department of Rheumatology and Immunology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, ²Department of Rheumatology and Immunology of the First People’s Hospital of Jingzhou, Jingzhou, China, ³ITabMed Ltd. Changchun, Shanghai, China
Background/Purpose: CD19 CAR T treatment has demonstrated clinical benefits to patients with severe/refractory systemic lupus erythematosus (SLE), possibly due to resetting autoimmunity. A-319, a highly…
Abstract Number: 0181 • ACR Convergence 2024
Integrated Multidisciplinary Lupus Social Work Program to Manage Social Determinants of Health in SLE and Lupus Nephritis – Preliminary Results
Kimberly DeQuattro¹, Stephanie DeVaughn², Andrew Kanoff³ and Abdallah Geara¹, ¹University of Pennsylvania, Philadelphia, PA, ²Uniersity of Pennsylvania, Pennsylvania, ³University of Pennsylvania, Philadelphia, PA, Philadelphia, PA
Background/Purpose: Minoritized individuals with systemic lupus erythematosus (SLE) experience social determinants of health (SDOH) challenges that affect access to care and increase the risk for…
Abstract Number: 0653 • ACR Convergence 2024
Impact of Lupus Nephritis on Neuropsychiatric SLE Outcomes
Pu-Jun Fang¹, Ping Hsuan Kuo² and Chun Chi Lu¹, ¹Tri-service general hospital, Taipei, Taiwan (Republic of China), ²Taipei Veterans General Hospital, Taipei City, Taiwan (Republic of China)
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disorder with diverse organ involvement, notably affecting the kidneys and nervous system. Lupus nephritis (LN) and neuropsychiatric…
Abstract Number: 1488 • ACR Convergence 2024
Clinical Utility and Performance of Anti-C1q Antibodies for Systemic Lupus Erythematosus: Comparative Analysis of Three Different Assays
Mariana Gonzalez-Trevino¹, MeLea Hetrick¹, Alain Sanchez-Rodriguez², Ali Duarte-Garcia¹ and Anne Tebo³, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic College of Medicine and Science, Rochester, MN, ³Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN
Background/Purpose: SLE is an autoimmune disorder characterized by autoantibody-mediated tissue damage. Antibodies against C1q (anti-C1q) can identify patients with LN and rising titers predict renal…
Abstract Number: 1686 • ACR Convergence 2024
Urine Proteomics in Class II Lupus Nephritis Reveals Immune Activation and Pro-Fibrotic Signatures
Jasmine Shwetar¹, Jill Buyon², Michelle Petri³, Kelly Ruggles⁴ and Andrea Fava⁵, ¹New York School of Medicine, Ann Arbor, MI, ²NYU Grossman School of Medicine, New York, NY, ³Johns Hopkins University School of Medicine, Timonium, MD, ⁴NYU Grossman School of Medicine, Brooklyn, NY, ⁵Johns Hopkins University, Baltimore, MD
Background/Purpose: Lupus nephritis (LN) is a pathologically diverse autoimmune disease that can lead to end-stage kidney disease and mortality. Although Class II LN is considered…
Abstract Number: 2381 • ACR Convergence 2024
Clinical Characteristics, Readmission Rates, and Outcomes in Lupus Patients with and Without Nephritic Involvement: Analysis from a National Database
Kishan Patel¹, Shivang Chaudhary², Simran Bhimani³, Yash Deshpande³, Leighton Hope² and Chaitanya Rojulpote², ¹Riverside Community Hospital, Riverside, CA, ²Saint Louis University, St. Louis, MO, ³The Wright Center for graduate medical education, Scranton, PA
Background/Purpose: Lupus nephritis (LN) is a complication of systemic lupus erythematosus (SLE) that occurs in 50 percent of patients. LN serves as an important predictor…
Abstract Number: 0182 • ACR Convergence 2024
Pilot Volunteer Lupus Navigator Program – Leveraging Community Health Workers to Address Social Determinants of Health in SLE
Patricia Nogueira De Sa¹, Stephanie Wirtshafter¹, Abdallah Geara² and Kimberly DeQuattro², ¹University of Pennsylvania, Pennsylvania, ²University of Pennsylvania, Philadelphia, PA
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic, multisystem autoimmune condition that disproportionally affects individuals from racial and ethnic minority groups with more than 95%…
Abstract Number: 0657 • ACR Convergence 2024
Data-driven Bayesian Network Analysis for Predicting Difficult-to-treat (DTT) Lupus Nephritis
Jagan K L¹, Augustine Jose², Vishnupriya G¹, Dellan S¹, Dhanush S¹, Samskruthi Reddy Tokala¹, Bhavana Mashetty¹, Chengappa Kavadichanda³, Sachith ganapathy¹, Aishwarya Gopal⁴, Rithik Roshan¹, Sareddy Sai vignesh Reddy¹, Sonal Mehra⁵, Molly Thabah¹ and Vir Singh Negi⁶, ¹Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, Puducherry, India, ²Jawaharlal Institute of Postgraduate Medical Education and Research, Gorimedu, Puducherry, India, ³Jawaharlal Institute of Postgraduate Medical Education and Research, pondicherry, Puducherry, India, ⁴Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Pondicherry, Puducherry, India, ⁵JAYPEE HOSPITAL, Noida, Uttar Pradesh, India, ⁶AIIMS, Bilaspur, Puducherry, Puducherry, India
Background/Purpose: Lupus nephritis (LN) is a serious manifestation of systemic lupus erythematosus (SLE), with 14-33% failing to respond to standard treatments. This study assesses treatment…
Abstract Number: 1489 • ACR Convergence 2024
Lupus Nephritis Clinical and Serological Responses at 12 Months: Implications for Repeat Biopsy, Intensified Immunosuppression or Additional Anti-proteinuric Therapy
H Michael Belmont¹, Brooke Cohen², Amit Saxena², Peter Izmirly³ and Jill Buyon⁴, ¹NYU School of Medicine, New York, NY, ²NYU Grossman School of Medicine, New York, NY, ³New York University Grossman School of Medicine, New York, NY, ⁴New York University Grossman School of Medicine, New York, NY
Background/Purpose: LN treatment goal is to suppress immune mediated injury and preserve eGFR. Studies indicate proteinuria < 700 at 12 months predicts maintaining eGFR at…
Abstract Number: 1796 • ACR Convergence 2024
Kidney Hematopoietic Stem and Progenitor Cells Contribute to Immune Cell Development and Pathology in Lupus Nephritis
Hansol Yi¹, Seyoung Jung², Mi-Ra Cho³, Yong-Gil Kim¹, Chang-Keun Lee¹, Bin Yoo¹, Jeongseok Lee² and Seokchan Hong¹, ¹Asan medical center, Seoul, Republic of Korea, ²Korea Advanced Institute of Science and Technology, Daejeon, Republic of Korea, ³Asan medical center, University of Ulsan College of Medicine, Seoul, Republic of Korea
Background/Purpose: Hematopoiesis primarily occurs in the bone marrow (BM), where hematopoietic stem and progenitor cells (HSPCs) originate. However, non-lymphoid tissues outside the BM can contribute…
Abstract Number: 2382 • ACR Convergence 2024
Utility of Urinary Biomarkers to Predict Long-term Renal Outcomes in Lupus Nephritis
Ryan Baker¹, Laura Patricia Whittall Garcia¹, Michael Kim¹, Dennisse Bonilla¹, Murray Urowitz², Dafna Gladman³, Zahi Touma⁴ and Joan Wither¹, ¹University Health Network, Toronto, ON, Canada, ²Self employed, Toronto, ON, Canada, ³University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁴University of Toronto, Toronto, ON, Canada
Background/Purpose: Lupus nephritis (LN) affects up to 50% of patients with Systemic Lupus Erythematosus. Around 40% of patients will experience a subsequent renal flare in…
Abstract Number: 0199 • ACR Convergence 2024
Delivery of Guideline Concordant Care in Childhood-Onset Lupus Nephritis
Alisha Akinsete¹, Mangala Rajan², Orysya Soroka², Karen Onel³, Monika Safford² and Iris Navarro Millan⁴, ¹Weill Cornell Medicine/ Hospital for Special Surgery, New York, NY, ²Weill Cornell Medicine, New York, NY, ³HSS, New York, NY, ⁴Weill Cornell Medicine, Hospital for Special Surgery, New York, NY
Background/Purpose: 50-80% of children with childhood-onset systemic lupus erythematosus (cSLE) develop lupus nephritis (LN). Children from historically marginalized communities are disproportionately affected by cSLE and…
Abstract Number: 0658 • ACR Convergence 2024
Zetomipzomib (KZR-616), a First-in-Class Selective Immunoproteasome Inhibitor, Demonstrated Improvements in SLE/LN Disease Measures and Biomarkers in Patients with Highly Active SLE or Nephrotic Range Proteinuria in the Open-label Phase 1b/2 MISSION Study
Richard Furie¹, Amit Saxena², Samir Parikh³, Richard Leff⁴, Lucas Bohnett⁵, Kathryn Ray⁶, Brian Tuch⁴, Janet Anderl⁴, Jennifer Whang⁴ and Kiruthi Palaniswamy⁷, ¹Northwell Health, Manhasset, NY, ²NYU School of Medicine, New York, NY, ³Ohio State University, Columbus, OH, ⁴Kezar Life Sciences, South San Francisco, CA, ⁵Kezar Life Sciences, El Cajon, ⁶Kezar Life Sciences, Mill Valley, CA, ⁷Kezar Life Sciences, Inc, South San Francisco, CA
Background/Purpose: Zetomipzomib is a selective inhibitor of the immunoproteasome with anti-inflammatory and immunomodulatory potential without evidence of immunosuppression to date. The MISSION study (NCT03393013), a…
Abstract Number: 1493 • ACR Convergence 2024
How Do Lupus Nephritis Patients Who Achieve Renal Remission Fare? A 3-year Comparison in Terms of GFR Decline
Jorge Guerra Sayre¹, Andrea Fava², Daniel Goldman³, Laurence Magder⁴ and Michelle Petri³, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Johns Hopkins University, Baltimore, MD, ³Johns Hopkins University School of Medicine, Timonium, MD, ⁴University of Maryland, Baltimore, Baltimore, MD
Background/Purpose: Lupus nephritis (LN) occurs in over 50% of SLE patients, contributing significant morbidity and mortality. Despite a generally accepted treatment goal of Complete Renal…
Abstract Number: 1798 • ACR Convergence 2024
CXCL6 Synthesized by Proximal Tubule Cells May Promote Fibrosis in Lupus Nephritis
Philip Carlucci¹, Nalani Sachan², Andrea Fava³, Brooke Cohen², Jasmine Shwetar⁴, Siddarth Gurajala⁵, Qian Xiao⁵, Joseph Mears⁶, Katie Preisinger², Devyn Zaminski⁷, Kristina Deonaraine⁸, Peter Izmirly⁹, Judith James¹⁰, Joel Guthridge¹⁰, Wade DeJager¹¹, David Wofsy¹², Cynthia Loomis², Gyles Ward², Ming Wu¹³, Chaim Putterman¹⁴, Deepak Rao¹⁵, Betty Diamond¹⁶, Derek Fine¹⁷, Jose Monroy-Trujillo¹⁷, H Michael Belmont⁷, William Apruzzese¹⁸, Anne Davidson¹⁹, Richard Furie²⁰, Paul Hoover²¹, Celine Berthier²², Maria Dall'Era²³, Diane Kamen²⁴, Kenneth Kalunian²⁵, Jennifer Anolik²⁶, Jennifer Barnas²⁷, Arnon Arazi²⁸, Soumya Raychaudhuri²⁹, Nir Hacohen³⁰, Robert Clancy³¹, Kelly Ruggles³², Michelle Petri³³ and Jill Buyon², and the Accelerating Medicines Partnership in RA/SLE, ¹New York University School of Medicine, New York, NY, ²NYU Grossman School of Medicine, New York, NY, ³Johns Hopkins University, Baltimore, MD, ⁴New York School of Medicine, Ann Arbor, MI, ⁵Harvard Medical School, Boston, MA, ⁶Michigan University, Ann Arbor, MI, ⁷NYU School of Medicine, New York, NY, ⁸Jacobs School of Medicine, University at Buffalo, Buffalo, NY, ⁹New York University Grossman School of Medicine, New York, NY, ¹⁰Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹¹Oklahoma Medical Research Foundation, Oklahoma City, ¹²University of California San Francisco, SF, CA, ¹³Northwell, New York, NY, ¹⁴Albert Einstein College of Medicine, Safed, Israel, ¹⁵Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ¹⁶The Feinstein Institutes for Medical Research, Manhasset, NY, ¹⁷Johns Hopkins School of Medicine, Baltimore, MD, ¹⁸Brigham and Women's Hospital, Everett, MA, ¹⁹Feinstein Institutes for Medical Research, Manhasset, NY, ²⁰Northwell Health, Manhasset, NY, ²¹Brigham and Women's Hospital, SWAMPSCOTT, MA, ²²University of Michigan, Ann Arbor, MI, ²³UCSF, Corte Madera, CA, ²⁴Medical University of South Carolina, Charleston, SC, ²⁵University of California San Diego, La Jolla, CA, ²⁶University of Rochester Medical Center, Rochester, NY, ²⁷University of Rochester, Rochester, NY, ²⁸Feinstein Institutes for Medical Research, Melrose, MA, ²⁹Brigham and Women's Hospital, Boston, MA, ³⁰Broad Institute of MIT and Harvard, Boston, MA, ³¹Columbia University Medical Center, New York, NY, ³²NYU Grossman School of Medicine, Brooklyn, NY, ³³Johns Hopkins University School of Medicine, Timonium, MD
Background/Purpose: Detection of urinary CXCL6, a member of the IL-8 chemokine family, has been linked to CKD and is a proposed marker of chronic damage…

1
2
3
…
37
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].